Urothelial Carcinoma BladderNCT04712201
En Bloc Bladder Tumor Resection: Prospective Randomized Study
A study testing En bloc transurethral resection of bladder tumor (TURBT) and Conventional TURBT in people with Urothelial Carcinoma Bladder and Bladder Cancer, run by Fundacio Puigvert at 1 site in Spain.
Trial summary
INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract. Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors, which are treatable through endourological procedures. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Urothelial Carcinoma Bladder, Bladder Cancer
- What is being tested?
- En bloc transurethral resection of bladder tumor (TURBT) and Conventional TURBT
- Type of treatment
- Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 300 participants
- Where
- 1 siteSpain
- Study dates
- 1 Apr 2018to 1 Apr 2026
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Unifocal primary or recurrent bladder cancer with size less or equal than 3 cm
- Multifocal primary or recurrent bladder cancer less or equal than 3 lesions and with size less or equal than 3 cm
Who cannot join
- Evidence of > 3 tumors or > 3 cm
- Computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher)
- Computed tomography/magnetic resonance evidence of distant metastases
Trial locations and contacts
1 site in 1 country.
Spain1 site, 1 recruiting
- Recruiting
Fundacio Puigvert
Barcelona, 08025
Andrea Gallioli, MD, 0034934169730, agallioli@fundacio-puigvert.es
About this study
Official title: En Bloc Bladder Tumor Resection: Prospective Randomized Evaluation of Monopolar, Bipolar and Laser Energy
INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract. Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors, which are treatable through endourological procedures. The current standard is based on conventional transurethral resection of bladder tumor, although high rates of recurrence have been reported following resection of the primary tumor. Given the importance of a correct initial diagnosis in these cases, en bloc transurethral resection has developed over the past 2 decades. This technique was born, according to the literature, with 3 main objectives: to improve the quality of the surgical piece for its anatomopathological reading, reduce the rate of postoperative complications and reduce the rate of relapses in the surgical bed. This technique is used as a common practice of tumor resection in other centers and has been shown in multiple publications that it does not increase surgical risk or negatively affect cancer results.
OBJECTIVE The objective of our study is to compare feasibility, perioperative complication rate, accuracy of staging and recurrence/progression rates when performing en bloc resection by means of different energies: monopolar, bipolar and laser energy.
Read more
MATERIAL AND METHODS Between April 2018 and June 2021, a prospective randomized study will be conducted including patients undergoing a transurethral resection of initial or recurrent bladder tumor, either unifocal or multifocal. Patients with tumors less than 3 cm and with less than 3 tumors shall be included if multiple. Patients with more than 3 tumors or tumors over 3cm, those with evidence of invasive muscle tumor(cT2) or those with evidence of remote metastasis, whether lymphatic or organic, will be excluded.
Patients will be randomized into two groups:
- Group 1 (test): en bloc resection (n-180). It will be divided into 3 subgroups according to the energy used (monopolar, bipolar, laser energy).
- Group 2 (control): Conventional transurethral resection (n-120). It will be divided into 2 subgroups depending on the energy used (monopolar or bipolar).
A fact sheet will be given to the patient about the study and the signature of the informed consent will be requested in order to be included. The patient will be free to leave the study at any time without having to provide any justification and without affecting the treatment, intervention and follow-up that must be carried out.
The processing and storage of samples will be carried out in the pathological anatomy laboratory, according to standard clinical practice.
Patients will be monitored according to the usual clinical practice protocol (minimum 5-year follow-up), included in the non-muscle invasive bladder tumor protocols of the Puigvert Foundation.
- Conditions
- Urothelial Carcinoma Bladder, Bladder Cancer
- Being tested
- En bloc transurethral resection of bladder tumor (TURBT), Conventional TURBT
- Keywords
- TURBT, En bloc, Urothelial cancer
- Medical subject headings
- Urinary Bladder Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
En bloc transurethral resection of bladder tumor (TURBT)Procedure or surgery
En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy
Conventional TURBTProcedure or surgery
Conventional transurethral resection of bladder tumor using monopolar and bipolar energy
| Study group | Role | What they receive |
|---|---|---|
| En bloc | Experimental | En bloc transurethral resection of the bladder Receives: Procedure: En bloc transurethral resection of bladder tumor (TURBT) |
| Conventional | Active comparator | Conventional transurethral resection of the bladder Receives: Procedure: Conventional TURBT |
What is being measured
The primary outcome is the main question the study is designed to answer.
Staging of bladder tumor
Evaluation of muscle presence in the specimen
Measured: Three years
Secondary outcomes (8)
Intraoperative complications
Bladder perforation grading, obturatory reflex, conversions to conventional TURB
Measured: Three years
Rate of planned adjuvant treatment
Rate of planned postoperative single instillation of mitomycin/epirubicin
Measured: Three years
Post-operative complications
Post-operative complications according to Clavien-Dindo System
Measured: Three years
Substaging T1 bladder cancer
T1a, T1b and T1c
Measured: Three years
Recurrence-free survival
Recurrence of bladder cancer
Measured: Through study completion, an average of five years
Progression-free survival
Progression of bladder cancer
Measured: Through study completion, an average of five years
Disease-free survival
Disease-free survival
Measured: Through study completion, an average of five years
Cancer specific survival
Cancer specific survival
Measured: Through study completion, an average of five years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted15 Jan 2021
- Study start1 Apr 2018
- Primary completion1 Jun 2021 (estimated)
- Study completion1 Apr 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Urothelial Carcinoma BladderStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind
- Who is masked
- Outcomes assessor
- Enrolment
- 300 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Fundacio Puigvert
- Sponsor type
- University, hospital or other
- Collaborators
- KARL STORZ Endoscopy-America, Inc.
- Responsible party
- Principal investigator, Alberto Breda, Fundacio Puigvert
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04712201
- Sponsor's protocol ID
- 2017/09c
- Status last verified
- Jan 2021
- First submitted
- 12 Jan 2021
- Last updated
- 15 Jan 2021
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Gallioli A, Diana P, Fontana M, Territo A, Rodriguez-Faba O, Gaya JM, Sanguedolce F, Huguet J, Mercade A, Piana A, Aumatell J, Bravo-Balado A, Algaba F, Palou J, Breda A. En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial. Eur Urol Oncol. 2022 Aug;5(4):440-448. doi: 10.1016/j.euo.2022.05.001. Epub 2022 May 23.
PubMed 35618567
Study at a glance
From the registry record, last updated by the sponsor on 15 Jan 2021. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- En Bloc Bladder Tumor Resection: Prospective Randomized Evaluation of Monopolar, Bipolar and Laser Energy
- ClinicalTrials.gov ID
- NCT04712201
- Acronym / sponsor ID
- 2017/09c
- Conditions
- Urothelial Carcinoma Bladder, Bladder Cancer
- Keywords
- TURBT, En bloc, Urothelial cancer
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 300 participants (estimated)
- Lead sponsor
- Fundacio PuigvertUniversity, hospital or other
- Collaborators
- KARL STORZ Endoscopy-America, Inc.
- Study start
- 1 Apr 2018 (actual)
- Primary completion
- 1 Jun 2021 (estimated)
- Study completion
- 1 Apr 2026 (estimated)
- First posted
- 15 Jan 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
INTRODUCTION Bladder tumor is the second most common neoplasm in the genitourinary tract. Most cases of ex novo diagnosis of bladder cancers are present as non-invasive muscle tumors, which are treatable through endourological procedures. The current standard is based on conventional transurethral resection of bladder tumor, although high rates of recurrence have been reported following resection of the primary tumor. Given the importance of a correct initial diagnosis in these cases, en bloc transurethral resection has developed over the past 2 decades. This technique was born, according to the literature, with 3 main objectives: to improve the quality of the surgical piece for its anatomopathological reading, reduce the rate of postoperative complications and reduce the rate of relapses in the surgical bed. This technique is used as a common practice of tumor resection in other centers and has been shown in multiple publications that it does not increase surgical risk or negatively affect cancer results.
OBJECTIVE The objective of our study is to compare feasibility, perioperative complication rate, accuracy of staging and recurrence/progression rates when performing en bloc resection by means of different energies: monopolar, bipolar and laser energy.
MATERIAL AND METHODS Between April 2018 and June 2021, a prospective randomized study will be conducted including patients undergoing a transurethral resection of initial or recurrent bladder tumor, either unifocal or multifocal. Patients with tumors less than 3 cm and with less than 3 tumors shall be included if multiple. Patients with more than 3 tumors or tumors over 3cm, those with evidence of invasive muscle tumor(cT2) or those with evidence of remote metastasis, whether lymphatic or organic, will be excluded.
Patients will be randomized into two groups:
- Group 1 (test): en bloc resection (n-180). It will be divided into 3 subgroups according to the energy used (monopolar, bipolar, laser energy).
- Group 2 (control): Conventional transurethral resection (n-120). It will be divided into 2 subgroups depending on the energy used (monopolar or bipolar).
A fact sheet will be given to the patient about the study and the signature of the informed consent will be requested in order to be included. The patient will be free to leave the study at any time without having to provide any justification and without affecting the treatment, intervention and follow-up that must be carried out.
The processing and storage of samples will be carried out in the pathological anatomy laboratory, according to standard clinical practice.
Patients will be monitored according to the usual clinical practice protocol (minimum 5-year follow-up), included in the non-muscle invasive bladder tumor protocols of the Puigvert Foundation.
Study design
- Primary purpose
- Diagnosis
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Single blind (outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| En bloc | Experimental | Procedure: En bloc transurethral resection of bladder tumor (TURBT)En bloc transurethral resection of the bladder |
| Conventional | Active comparator | Procedure: Conventional TURBTConventional transurethral resection of the bladder |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (2 listed)
- Unifocal primary or recurrent bladder cancer with size less or equal than 3 cm
- Multifocal primary or recurrent bladder cancer less or equal than 3 lesions and with size less or equal than 3 cm
Key exclusion criteria (3 listed)
- Evidence of > 3 tumors or > 3 cm
- Computed tomography/cystoscopy suspect of muscle-invasive bladder cancer (cT2 or higher)
- Computed tomography/magnetic resonance evidence of distant metastases
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| En bloc transurethral resection of bladder tumor (TURBT)En bloc transurethral resection of bladder tumor using thulium:yttrium aluminium garnet, monopolar and bipolar energy | Procedure or surgery | En bloc |
| Conventional TURBTConventional transurethral resection of bladder tumor using monopolar and bipolar energy | Procedure or surgery | Conventional |
Primary outcome
Staging of bladder tumor
Time frame: Three years
Evaluation of muscle presence in the specimen
8 secondary outcomes
Intraoperative complications
Time frame: Three years
Rate of planned adjuvant treatment
Time frame: Three years
Post-operative complications
Time frame: Three years
Substaging T1 bladder cancer
Time frame: Three years
Recurrence-free survival
Time frame: Through study completion, an average of five years
Progression-free survival
Time frame: Through study completion, an average of five years
Disease-free survival
Time frame: Through study completion, an average of five years
Cancer specific survival
Time frame: Through study completion, an average of five years
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 Jan 2021.
- Derived from this study: PubMed 35618567Gallioli A, Diana P, Fontana M, Territo A, Rodriguez-Faba O, Gaya JM, Sanguedolce F, Huguet J, Mercade A, Piana A, Aumatell J, Bravo-Balado A, Algaba F, Palou J, Breda A. En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority Trial. Eur Urol Oncol. 2022 Aug;5(4):440-448. doi: 10.1016/j.euo.2022.05.001. Epub 2022 May 23.
Related trials for Urothelial Carcinoma Bladder
Active, not recruitingPhase 2
Study BT8009-230 in Participants With Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Metastatic Urothelial Cancer
RecruitingPhase 2/3
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study
Muscle Invasive Bladder Urothelial Carcinoma, Muscle Invasive Renal Pelvis Urothelial Carcinoma
RecruitingPhase 3
Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)
Urothelial Cancer, Urinary Bladder Neoplasms
RecruitingPhase 2
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma
Active, not recruitingPhase 1/2
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing En bloc transurethral resection of bladder tumor (TURBT) and Conventional TURBT in people with Urothelial Carcinoma Bladder and Bladder Cancer, run by Fundacio Puigvert at 1 site in Spain.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 15 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Spain. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
Contact Andrea Gallioli, MD (0034934169730, agallioli@fundacio-puigvert.es), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Staging of bladder tumor (time frame: Three years). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04712201, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Jan 2021.